Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition

References

• Benavent Acero, F., et al., 2017. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung cancer, 107, 14–21.
   PubMed Web of Science ®Google Scholar
• Bhatia, S., et al., 2019. Interrogation of phenotypic plasticity between epithelial and mesenchymal states in breast cancer. Journal of clinical medicine, 8, 1–24.
   Web of Science ®Google Scholar
• Cai, D., et al., 2014. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials, 35, 2283–2294.
   PubMed Web of Science ®Google Scholar
• Cao, Z., et al., 2013. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. European journal of cancer, 49, 3914–3923.
   PubMed Web of Science ®Google Scholar
• Devlin, E.J., Denson, L.A., and Whitford, H.S., 2017. Cancer treatment side effects: a meta-analysis of the relationship between response expectancies and experience. Journal of pain and symptom management, 54, 245–258 e2.
   PubMed Web of Science ®Google Scholar
• Guo, M., et al., 2016. Migration suppression of small cell lung cancer by polysaccharides from Nostoc Commune Vaucher. Journal of agricultural and food chemistry, 64, 6277–6285.
   PubMed Web of Science ®Google Scholar
• He, R., Zhang, F.H., and Shen, N., 2017. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomedicine & pharmacotherapy = biomedecine & pharmacotherapie, 95, 331–338.
   PubMed Web of Science ®Google Scholar
• Hu, K.Y., et al., 2014. Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B. Yao xue xue bao = acta pharmaceutica sinica, 49, 1007–1012.
   PubMedGoogle Scholar
• Jiang, Y., et al., 2015. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway. Biomedicine & pharmacotherapy = biomedecine & pharmacotherapie, 74, 77–82.
   PubMed Web of Science ®Google Scholar
• Kraft, J.C., et al., 2014. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. Journal of pharmaceutical sciences, 103, 29–52.
   PubMed Web of Science ®Google Scholar
• Li, C., et al., 2018a. Long non-coding RNA XIST promotes TGF-beta-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. Cancer letters, 418, 185–195.
   PubMed Web of Science ®Google Scholar
• Li, C.H., et al., 2017. Cytoplasmic aryl hydrocarbon receptor regulates glycogen synthase kinase 3 beta, accelerates vimentin degradation, and suppresses epithelial-mesenchymal transition in non-small cell lung cancer cells. Archives of toxicology, 91, 2165–2178.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2007. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical cancer research: an official journal of the American association for cancer research, 13, 6753–6760.
   PubMed Web of Science ®Google Scholar
• Li, X.T., et al., 2015. The antitumor activity of PNA modified vinblastine cationic liposomes on Lewis lung tumor cells: in vitro and in vivo evaluation. International journal of pharmaceutics, 487, 223–233.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2018b. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene. Molecular carcinogenesis, 57, 125–136.
   PubMed Web of Science ®Google Scholar
• Liu, J.J., et al., 2019. Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artificial cells, nanomedicine, and biotechnology, 47, 1947–1960.
   PubMed Web of Science ®Google Scholar
• Liu, Z., et al., 2012. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One, 7, e40480.
   PubMed Web of Science ®Google Scholar
• Luo, Q., et al., 2017. ATB(0,+) transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes. Biomaterials science, 5, 295–304.
   PubMed Web of Science ®Google Scholar
• Ma, Z., et al., 2019. Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment. International journal of nanomedicine, 14, 2029–2053.
   PubMed Web of Science ®Google Scholar
• Ming, X., et al., 2016. Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update. Medicine, 95, e5051.
   PubMed Web of Science ®Google Scholar
• Muller, D.C., Johansson, M., and Brennan, P., 2017. Lung cancer risk prediction model incorporating lung function: development and validation in the UK biobank prospective cohort study. Journal of clinical oncology: official journal of the american society of clinical oncology, 35, 861–869.
   PubMed Web of Science ®Google Scholar
• Palazzolo, S., et al., 2018. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes. Current medicinal chemistry, 25, 4224–4268.
   PubMed Web of Science ®Google Scholar
• Pancewicz-Wojtkiewicz, J., 2016. Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer medicine, 5, 3572–3578.
   PubMed Web of Science ®Google Scholar
• Popper, H.H., 2016. Progression and metastasis of lung cancer. Cancer metastasis reviews, 35, 75–91.
   PubMed Web of Science ®Google Scholar
• Pumerantz, A.S., 2012. PEGylated liposomal vancomycin: a glimmer of hope for improving treatment outcomes in MRSA pneumonia. Recent patents on anti-infective drug discovery, 7, 205–212.
   PubMedGoogle Scholar
• Rivankar, S., 2014. An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics, 10, 853–858.
   PubMed Web of Science ®Google Scholar
• Tandberg, D.J., et al., 2018. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer, 124, 667–678.
   PubMed Web of Science ®Google Scholar
• Tokarska-Schlattner, M., Wallimann, T., and Schlattner, U., 2006. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. Comptes rendus biologies, 329, 657–668.
   PubMed Web of Science ®Google Scholar
• Torre-Bouscoulet, L., et al., 2018. Longitudinal evaluation of lung function in patients with advanced non-small cell lung cancer treated with concurrent chemoradiation therapy. International journal of radiation oncology, biology, physics, 101, 910–918.
   PubMed Web of Science ®Google Scholar
• Veronesi, G., et al., 2015. When is surgery indicated for small-cell lung cancer? Lung cancer, 90, 582–589.
   PubMed Web of Science ®Google Scholar
• Walker, M.J., et al., 2015. Discovery and validation of predictive biomarkers of survival for non-small cell lung cancer patients undergoing radical radiotherapy: two proteins with predictive value. EBioMedicine, 2, 841–850.
   PubMed Web of Science ®Google Scholar
• Wang, G., et al., 2018. Prognostic value of twist, snail and E-cadherin expression in pathological N0 non-small-cell lung cancer: a retrospective cohort study. European journal of cardio-thoracic surgery, 54 (2), 237–245.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2014. Oxidored-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: inhibition of EMT in vitro and in vivo in mice. Cancer letters, 348, 109–118.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2010. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Therapeutic delivery, 1, 273–287.
   PubMedGoogle Scholar
• Wang, Y., et al., 2019. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. International journal of nanomedicine, 14, 4071–4090.
   PubMed Web of Science ®Google Scholar
• Wille, M.M., et al., 2016. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. American journal of respiratory and critical care medicine, 193, 542–551.
   PubMed Web of Science ®Google Scholar
• Xie, Y., et al., 2018. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Molecular oncology, 12, 648–658.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2014. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting twist in human epithelial cancer. Molecular cancer, 13, 121.
   PubMed Web of Science ®Google Scholar
• Yu, W., et al., 2011. Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer chemotherapy and pharmacology, 68, 619–629.
   PubMed Web of Science ®Google Scholar
• Yue, W.Y. and Chen, Z.P., 2006. Vasculogenic mimicry–potential target for tumor therapy. Ai zheng = aizheng = chinese journal of cancer, 25, 914–916.
   PubMedGoogle Scholar
• Zahedi, A., et al., 2018. Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes. Lung cancer, 122, 224–233.
   PubMed Web of Science ®Google Scholar
• Zhan, X.S., et al., 2019. A comparative study of biological characteristics and transcriptome profiles of mesenchymal stem cells from different canine tissues. International journal of molecular sciences, 20 (6), 1485.
   Web of Science ®Google Scholar
• Zhang, Y., et al., 2018. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. Cancer letters, 419, 75–83.
   PubMed Web of Science ®Google Scholar
• Zhao, H., et al., 2018. p0071 interacts with E-cadherin in the cytoplasm so as to promote the invasion and metastasis of non-small cell lung cancer. Molecular carcinogenesis, 57, 89–96.
   PubMed Web of Science ®Google Scholar